Imatinib

Refractory Malignancy

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 95/ 100

Competitive context

181 Active assets in the Refractory Malignancy cohort.

Asset / Sponsor	Phase	Rating
Catequentinib Nanfang Hospital, Southern Medical University	Phase 3	BB
Irinotecan M.D. Anderson Cancer Center	Phase 2	BB
Durvalumab OHSU Knight Cancer Institute	Phase 2	BB
Cediranib National Cancer Institute (NCI)	Phase 2	BB
Sugemalimab Second Affiliated Hospital of Soochow University	Phase 2	BB

View all 50 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

71 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

71 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.